Kumar Emil, Okosun Jessica
Department of Haematology, King's College Hospital, London, UK.
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70070. doi: 10.1002/hon.70070.
Significant strides have been made in the treatment of follicular lymphoma, leading to improvements in long-term patient outcomes. However, the disease's heterogeneity presents challenges in selecting the optimal therapy at each stage of treatment. The expanding array of therapeutic options introduces new complexities, including making the right initial choice, sequencing treatments effectively, and redefining treatment goals. As the landscape evolves, there is a growing need to shift toward precision-based treatment decisions, potentially guided by underlying disease biology. Here, we explore recent advancements in both upfront and relapsed/refractory treatment strategies, addressing considerations in therapy selection, and the current progress toward precision approaches with its potential to enhance decision-making.
在滤泡性淋巴瘤的治疗方面已取得显著进展，使患者的长期预后得到改善。然而，该疾病的异质性在治疗的每个阶段选择最佳治疗方案时带来了挑战。不断扩大的治疗选择范围带来了新的复杂性，包括做出正确的初始选择、有效安排治疗顺序以及重新定义治疗目标。随着情况的演变，越来越需要转向基于精准的治疗决策，这可能由潜在的疾病生物学来指导。在此，我们探讨了一线治疗和复发/难治性治疗策略的最新进展，讨论了治疗选择中的注意事项，以及精准治疗方法的当前进展及其在改善决策方面的潜力。
